F. Hoffmann-La Roche Ltd. has moved closer to securing European approval for Susvimo after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the continuous-delivery treatment for adults with neovascular age-related macular degeneration. The proposed indication covers patients whose disease has become stable after previously responding to an intravitreal vascular endothelial growth factor inhibitor. Susvimo continuously releases ranibizumab through the surgically implanted and refillable Contivue ocular implant, potentially reducing treatment frequency from monthly eye injections to one refill every 24 weeks. A final European Commission decision is expected following the positive opinion adopted on July 23, 2026.
The recommendation could introduce the first continuous-delivery treatment for neovascular age-related macular degeneration in the European Union. However, Susvimo does not eliminate treatment procedures entirely. Eligible patients must undergo an outpatient surgical procedure to insert the implant, followed by specialist refill procedures and continued monitoring for potentially serious ocular complications.
How Susvimo could reduce frequent anti-VEGF injections for wet age-related macular degeneration
Neovascular age-related macular degeneration, also called wet age-related macular degeneration, develops when abnormal blood vessels grow beneath the macula and leak fluid or blood into the retina. The disease can rapidly damage the central vision required for reading, recognising faces and performing other detailed activities. Roche estimates that approximately 1.7 million people in the European Union are living with the condition.
Intravitreal anti-vascular endothelial growth factor medicines have transformed treatment by suppressing the biological signals that promote abnormal blood-vessel growth and leakage. Their effectiveness nevertheless depends on patients returning for repeated injections and monitoring. The burden can become especially difficult for older adults who rely on relatives or caregivers for transport to retinal clinics.
Susvimo is intended to address that treatment burden through continuous intraocular delivery. The system consists of a refillable implant placed in the eye during a one-time outpatient procedure and four ancillary devices used to fill, insert, refill or remove the implant. The implant contains a customised 100 mg/mL formulation of ranibizumab that is different from the conventional intravitreal formulation marketed as Lucentis.
Under the recommended European indication, the implant would be refilled every 24 weeks. This schedule could reduce planned treatment procedures to approximately two refills a year, compared with monthly ranibizumab injections in the pivotal clinical comparison. Roche reported that approximately 95% of Susvimo-treated participants did not require supplemental anti-vascular endothelial growth factor treatment between scheduled refills during longer-term follow-up.
The proposed label does not cover every person newly diagnosed with wet age-related macular degeneration. The European Medicines Agency said patients must first have achieved stable disease after responding to an intravitreal vascular endothelial growth factor inhibitor. That requirement allows ophthalmologists to confirm that the disease is responsive to this treatment mechanism before considering the surgical implant.
The implant must also be managed by an ophthalmologist experienced in vitreoretinal surgery and trained in its procedures. Susvimo may therefore reduce the frequency of repeated injections without turning wet age-related macular degeneration into a treatment that can be managed outside specialist eye centres.
What the Archway, LADDER and Portal studies showed about vision maintenance
The positive recommendation was supported by the Phase 3 Archway study, the Phase 2 LADDER study and the Portal long-term extension study. Archway randomly assigned previously treated wet age-related macular degeneration patients to receive Susvimo refills every 24 weeks or intravitreal ranibizumab injections every four weeks.
The European Medicines Agency concluded that Susvimo was comparable with monthly ranibizumab injections in maintaining visual and anatomical outcomes while substantially reducing treatment frequency. Roche reported that longer-term follow-up through Portal supported maintained vision for as long as seven years among participating patients who continued treatment.
These results support Susvimo as a durable delivery strategy rather than a more potent active medicine. Both treatment groups received ranibizumab, meaning the principal innovation lies in how the therapy is delivered and maintained inside the eye.
That distinction is clinically relevant. A patient who responds well to injected ranibizumab may be able to preserve the same biological treatment approach while reducing the number of scheduled injections. The implant may be less attractive for patients who are well controlled on increasingly extended injection schedules, are unsuitable for ocular surgery or prefer to avoid an implanted device.
The comparison with monthly ranibizumab also does not capture every current treatment option. Modern retinal practice includes medicines that can permit longer intervals between injections in selected patients. The practical advantage of Susvimo will therefore depend on how reliably it provides six-month control compared with other anti-vascular endothelial growth factor medicines used under treat-and-extend strategies.
The clinical programme shows that many patients can maintain vision with scheduled six-month refills. It does not guarantee that every patient will avoid supplemental treatment or remain controlled over the same interval. Ophthalmologists will still need to monitor retinal anatomy, visual function and signs of renewed disease activity.
Why the refillable ocular implant carries different risks from routine eye injections
Susvimo changes the treatment burden, but it also introduces risks associated with surgery, an implanted device and repeated refill procedures. The European Medicines Agency listed iritis, conjunctival bleb leakage, cataract, vitreous floaters, conjunctival haemorrhage, conjunctival redness, eye pain and headache among the most common adverse effects.
United States prescribing information provides additional context about the implant’s established safety profile. The label warns that Susvimo has been associated with an endophthalmitis rate up to three times higher than monthly intravitreal ranibizumab injections. Endophthalmitis is a serious infection inside the eye that can threaten vision and requires urgent treatment.
Other implant-related risks identified in the United States include retinal detachment, vitreous haemorrhage, conjunctival erosion or retraction, implant movement and septum dislodgement. These risks should not automatically be assumed to appear in identical language in the final European product information, which will be published after European Commission approval, but they illustrate why patient selection, surgical technique and follow-up will remain central to Susvimo use.
The product also carries an important manufacturing and commercial history. Genentech voluntarily recalled Susvimo components in the United States in October 2022 after testing identified implants that did not meet performance requirements and raised concerns about septum dislodgement. The company reintroduced the treatment in July 2024 after updating the implant and manufacturing process.
The European platform has since received a CE mark under the Contivue name. Roche said the platform includes the implant and ancillary devices required for insertion, refill and removal. The positive medicinal-product recommendation now brings the ranibizumab component closer to authorisation, but European adoption will depend on retinal specialists being trained in the full drug-device procedure.
The recall history does not negate the clinical benefit shown in Archway and Portal, but it means the commercial launch must establish confidence in both the medicine and the reliability of the implant. Device quality, surgical education and rapid recognition of complications will be as important as the durability of ranibizumab delivery.
What European approval could mean for Roche’s wider ophthalmology strategy
Susvimo would add a differentiated delivery platform to Roche’s ophthalmology portfolio, which already includes Vabysmo and established ranibizumab products. Rather than competing only through a new biological mechanism, Roche is attempting to address one of retinal medicine’s most persistent operational problems: maintaining long-term treatment adherence despite repeated clinic visits and eye injections.
The company is also evaluating whether other medicines could eventually be delivered through Contivue. If the platform can safely accommodate molecules with greater potency or durability, the implant could become more than a delivery system for ranibizumab. That possibility remains developmental and is not included in the current European recommendation.
Commercial uptake will depend on reimbursement for the implant procedure, the medicine and subsequent refills. Hospitals and retinal practices will also need trained surgeons, appropriate equipment and systems for long-term monitoring. These requirements could produce a gradual launch even if the European Commission grants approval.
Roche Holding Ltd.’s United States-traded American depositary receipt, $RHHBY, closed at approximately $53.92 on July 24, compared with a previous close of about $51.70. The gain coincided with the Susvimo recommendation but also followed Roche’s half-year business update, meaning the stock movement cannot be attributed solely to the ophthalmology news.
The regulatory recommendation validates Roche’s effort to transform a familiar anti-vascular endothelial growth factor medicine into a continuous-delivery product. The opportunity is meaningful because reducing injection frequency could help patients remain on treatment and ease pressure on retinal clinics. The commercial and clinical outcome will depend on whether those advantages are sufficient to justify ocular surgery, specialist training and the implant’s distinct safety risks.
